From the Research
Wellbutrin (bupropion) is a viable option for reducing vasomotor symptoms in menopause, particularly for women who cannot or prefer not to use hormonal treatments, as evidenced by the most recent study in 2025 1. The use of Wellbutrin for vasomotor symptoms is supported by its mechanism of action, which involves affecting brain neurotransmitters like dopamine and norepinephrine, thereby helping to stabilize the body's thermoregulatory system that becomes disrupted during menopause. Some key points to consider when using Wellbutrin for vasomotor symptoms include:
- Starting dose: 150 mg once daily for one week, then increasing to 150 mg twice daily if needed and tolerated
- Improvement time: 4-8 weeks to become noticeable
- Common side effects: insomnia, dry mouth, and headache
- Contraindications: seizure disorders, eating disorders, or those taking MAO inhibitors It's also important to note that while Wellbutrin may be effective in reducing vasomotor symptoms, it is not as effective as hormone replacement therapy, as stated in the study from 2023 2. Additionally, other nonhormonal options, such as SSRIs, SNRIs, gabapentin, and clonidine, may also be considered, as discussed in the study from 2015 3 and 2025 1. However, the most recent and highest quality study from 2025 1 provides the most up-to-date guidance on nonhormonal treatments for vasomotor symptoms, and should be prioritized when making treatment decisions. Overall, Wellbutrin can be a reasonable option for women with vasomotor symptoms who cannot or prefer not to use hormonal treatments, and its use should be considered in the context of the individual patient's needs and medical history, as supported by the study from 2025 1.